Combined Treatment with Fibrates and Small Doses of Atorvastatin in Patients with Mixed Hyperlipidemia

Reference

• Pajukanta P, Porkka KV Genetics of familial combined hyper-lipidemia. Curr Atheroscler Rep 1999;1:79–86
   PubMedGoogle Scholar
• Jacobson TA. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Curr Atheroscler Rep 2001;3:373–82
   PubMedGoogle Scholar
• Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 2000;109:261–2
   PubMed Web of Science ®Google Scholar
• Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998;19:355–71
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3:83–92
   PubMedGoogle Scholar
• Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin 2000;16:21–32
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Brewer HB Jr, Leitersdorf E for the Fibrate Consensus Group. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998;81:912–7
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Milionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 2000;56:631–5
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993;13:702–11
   PubMedGoogle Scholar
• Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, Joyo DM, Ganter SE. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138:151–5
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237–44
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Hatzikonstantinou HA, Didangelos TP, Carina MV, Kranitsaw DF, Kontopoulos AG. Safety and efficacy of long-term statin–fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608–13
   PubMed Web of Science ®Google Scholar
• Leitersdorf E, Muratti EN, Eliav O, Meiner V, Eisenberg S, Dann EJ, Sehayek E, Peters TK, Stein Y. Efficacy and safety of a combination fluvastatin–bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin–cholestyramine combination. Am J Med 1994;96:401–7
   PubMed Web of Science ®Google Scholar
• Eliav O, Schurr D, Pfister P, Freidlander Y, Leitersdorf E. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995;76:76A–79A
   PubMed Web of Science ®Google Scholar
• Smit JW, Jansen GH, de Bruin TW, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995;76:126A–128A
   PubMed Web of Science ®Google Scholar
• Farnier M, Dejager S for the French Fluvastatin Study Group. Effect of combined fluvastatin–fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol 2000;85:53–7
   PubMed Web of Science ®Google Scholar
• Pauciullo P, Brognino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000;150:429–36
   PubMed Web of Science ®Google Scholar
• Spieker LE, Noll G, Hannak M, Luscher TF. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharmacol 2000;35:361–5
   PubMed Web of Science ®Google Scholar
• Tuzgol S, Wang LD, Kastelein JJ. Tolerability and efficacy of gemfibrozil and simvastatin combination therapy in 263 dyslipidemic patients attending a lipid clinic. 66th Congress of the European Atherosclerosis Society 1996;Florence, Italy
   Google Scholar
• Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B–65B
   PubMed Web of Science ®Google Scholar
• Iliadis EA, Rosenson RS. Long-term safety of pravastatin–gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999;22:25–8
   PubMed Web of Science ®Google Scholar
• Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000;247:563–9
   PubMed Web of Science ®Google Scholar
• Bakker-Arkema RG, Davidson MH, Goldstein RJ, Diagnon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMGCoA reductase inhibitor in patients with hypertriglyceridemia. JAMA 1996;275:128–33
   PubMed Web of Science ®Google Scholar
• Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999;34:60–63
   PubMed Web of Science ®Google Scholar
• Achimastos A, Liberopoulos E, Nikas S, Bairaktari E, Miltiadous G, Tsimihodimos V, Elisaf M. The effects of the addition of micronized fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002;18(2):59–63
   PubMed Web of Science ®Google Scholar
• Kakafika A, Tsimihodimos V, Elisaf M. Effect of atorvastatin on serum uric acid levels. Atherosclerosis 2001;158:255
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 2001;16:1301
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol (in press)
   Google Scholar
• Kakafika A, Liamis G, Elisaf M, Mikhailidis D. Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 2001;17(3):230–1
   PubMed Web of Science ®Google Scholar